Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.
N Engl J Med. 2018.
PMID: 29860938
Free article.
Clinical Trial.
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM.
Roboz GJ, et al. Among authors: kapsalis sm.
Blood. 2020 Feb 13;135(7):463-471. doi: 10.1182/blood.2019002140.
Blood. 2020.
PMID: 31841594
Free PMC article.
Clinical Trial.
Item in Clipboard
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.
DiNardo CD, Stein EM, Pigneux A, Altman JK, Collins R, Erba HP, Watts JM, Uy GL, Winkler T, Wang H, Choe S, Liu H, Wu B, Kapsalis SM, Roboz GJ, de Botton S.
DiNardo CD, et al. Among authors: kapsalis sm.
Leukemia. 2021 Nov;35(11):3278-3281. doi: 10.1038/s41375-021-01229-x. Epub 2021 Mar 26.
Leukemia. 2021.
PMID: 33772143
Free PMC article.
No abstract available.
Item in Clipboard
Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.
Jiang X, Wada R, Poland B, Kleijn HJ, Fan B, Liu G, Liu H, Kapsalis S, Yang H, Le K.
Jiang X, et al.
Clin Transl Sci. 2021 May;14(3):942-953. doi: 10.1111/cts.12959. Epub 2021 Jan 25.
Clin Transl Sci. 2021.
PMID: 33493392
Free PMC article.
Clinical Trial.
Item in Clipboard
Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
DiNardo CD, Roboz GJ, Watts JM, Madanat YF, Prince GT, Baratam P, de Botton S, Stein AS, Foran JM, Arellano ML, Sallman DA, Hossain M, Marchione DM, Bai X, Patel PA, Kapsalis SM, Garcia-Manero G, Fathi AT.
DiNardo CD, et al. Among authors: kapsalis sm.
Blood Adv. 2024 Apr 19:bloodadvances.2023012302. doi: 10.1182/bloodadvances.2023012302. Online ahead of print.
Blood Adv. 2024.
PMID: 38640348
Item in Clipboard
Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study.
DiNardo CD, De Botton S, Pollyea DA, Stone RM, Altman JK, Fathi AT, Limsakun T, Liang M, Choe S, Hossain M, Tron AE, Meng Q, Kapsalis SM, Pandya SS, Stein EM.
DiNardo CD, et al. Among authors: kapsalis sm.
Am J Hematol. 2023 Sep;98(9):E233-E236. doi: 10.1002/ajh.27005. Epub 2023 Jun 24.
Am J Hematol. 2023.
PMID: 37354069
Clinical Trial.
No abstract available.
Item in Clipboard
Cite
Cite